When Bullous Pemphigoid Is Not Bullous Pemphigoid: The Importance of Going Beyond Direct Immunofluorescence

Christina R. Hopkins¹, Vicky Ren¹, Raminder Grover², Clay Cockerell³, Sylvia Hsu⁴

¹. Dermatology, Baylor College of Medicine, Houston, USA  ². Laboratory Medicine, Beutner Laboratories, Buffalo, USA  ³. Dermatology, University of Texas Southwestern Medical Center, Dallas, USA  ⁴. Dermatology, Temple University Hospital, Philadelphia, USA

Corresponding author: Vicky Ren, vzren@bcm.edu

Abstract

Bullous pemphigoid (BP) is the most common autoimmune bullous disease, but rarer forms of pemphigoid may appear identical to BP on routine histopathology and direct immunofluorescence (DIF). Here, we present the case of a 60-year-old man, who was initially thought to have BP, with supportive findings on routine histopathology and DIF. However, prominent oral involvement and cutaneous lesions refractory to conventional treatment suggested an alternate diagnosis. Further workup was performed, including indirect immunofluorescence (IIF) on salt-split skin, which showed binding of antibodies to the dermal floor rather than to the blister roof, and enzyme-linked immunosorbent assay for pemphigus and pemphigoid antibodies. With these additional tests, we concluded that the patient does not have BP but rather anti-p200 pemphigoid, anti-p105 pemphigoid, or a yet undiscovered form of pemphigoid. We reached a presumptive diagnosis of anti-p200 pemphigoid, as it is the most common pemphigoid with serum antibodies to the dermal floor of human salt-split skin by IIF. This case demonstrates that suspicion for other autoimmune bullous diseases in cases of treatment-refractory and clinically aberrant BP is essential. A limited workup may lead to a missed diagnosis and ultimately less efficient disease management.

Introduction

Bullous pemphigoid (BP), the most common autoimmune bullous disease (AIBD), features eosinophilic spongiosis or a subepidermal blister with eosinophils on routine histopathology and immunoglobulin G (IgG) and/or C3 basement membrane zone (BMZ) deposition on direct immunofluorescence (DIF) [1]. In cases where BP is refractory to treatment, the clinician should suspect rarer forms of pemphigoid, which can appear identical to BP on routine histopathology and DIF. Further workup is necessary in these instances [2-3]. Here, we present a case of presumptive anti-p200 pemphigoid and the diagnostic approach utilized.

Case Presentation

A 60-year-old man presented for evaluation of a generalized, blistering rash. Physical examination showed erythematous papules and vesicles - some in an annular, herpetiform arrangement - on the trunk, axillae, upper extremities (including palms and fingers), buttocks, inner thighs, and toes, as well as ulcers on the vermilion lips, tongue, and palate (Figures 1A-1B, Figures 2A-2D).

How to cite this article

Hopkins C R, Ren V, Grover R, et al. (February 14, 2022) When Bullous Pemphigoid Is Not Bullous Pemphigoid: The Importance of Going Beyond Direct Immunofluorescence. Cureus 14(2): e22201. DOI 10.7759/cureus.22201
An outside dermatologist had performed punch biopsies for routine histopathology and DIF on two separate occasions. Initial histopathology showed a subepidermal blister with neutrophils concerning for dermatitis herpetiformis (DH) or bullous systemic lupus erythematosus (SLE) while DIF showed a granular, linear band of IgG and C3 at the dermal-epidermal junction (DEJ) concerning for an unusual BP. However, subsequent histopathology and DIF were both consistent with BP. The patient trialed oral dapsone without improvement and had been on prednisone 50 mg daily for over a month with persistent flaring.
We started the patient on dupilumab while continuing prednisone; however, the significant oral involvement and recalcitrant cutaneous lesions suggested an AIBD other than BP, warranting further workup. Repeat biopsies showed a subepidermal vesicle with a mixed dermal infiltrate of lymphocytes, histiocytes, and eosinophils and a smooth band of IgG and C3 with an n-serration pattern along the DEJ, consistent with BP (Figures 3A-3C).

**FIGURE 3: Anti p-200 pemphigoid; routine histopathology and direct immunofluorescence**

A&B: Subepidermal blister with mixed dermal infiltrate of lymphocytes, histiocytes, and eosinophils (hematoxylin-eosin stain; x4 and x20 magnification, respectively); C: Linear band of IgG and C3 at the dermal-epidermal junction (white arrow) with n-serration (direct immunofluorescence; x20 magnification)

However, enzyme-linked immunosorbent assay (ELISA) for BP antibodies did not correlate with the extent of clinical disease: BP180 was low-positive (17.1U/ml; reference: negative <9U/ml) and BP230 was normal. Anti-nuclear antibody was negative, as was ELISA for antibodies to desmogleins 1 and 3, envoplakin 3, and type VII collagen, thus ruling out paraneoplastic pemphigus (PNP), pemphigus vulgaris (PV), pemphigus foliaceus (PF), epidermolysis bullosa acquisita (EBA), and bullous SLE. Indirect immunofluorescence (IIF) on the monkey esophagus and rat bladder epithelium was negative, thus eliminating PV and PNP, respectively. IIF on salt-split skin showed strong binding of IgG and IgG4 BMZ antibodies to the dermal floor (Figures 4A-4D), as is seen with EBA, anti-laminin 332 mucous membrane pemphigoid (MMP), anti-p105 pemphigoid, and anti-p200 pemphigoid.
FIGURE 4: Anti-p200 pemphigoid; indirect immunofluorescence on salt-split skin

A: IgG unsplit skin; B: IgG on 1.0 M NaCl split skin; C: IgG4 unsplit skin; D: IgG4 on 1.0 M NaCl split skin.

IgG and IgG4 basement membrane zone antibodies binding to the dermal floor on salt-split skin (white arrows)

In the United States, there are currently no commercially available tests for anti-laminin 332, anti-p105, or anti-p200 (laminin gamma-1). However, research testing for laminin 332 antibodies by IIF was negative for IgG and IgG4.

By this process of exclusion, we concluded that the patient does not have BP but rather anti-p200 pemphigoid, anti-p105 pemphigoid, or a yet undiscovered form of pemphigoid. We favor a diagnosis of anti-p200 pemphigoid, as it is the most common pemphigoid with serum antibodies to the dermal floor of human salt-split skin by IIF [4]. Furthermore, compared to BP, anti-p200 pemphigoid exhibits prominent mucosal, palmoplantar, and cephalic involvement and an earlier age of onset (mean age ~65 in anti-p200 pemphigoid versus 70+ in BP), as seen in our patient [3]. Anti-p105 pemphigoid is less likely, as it clinically resembles toxic epidermal necrolysis or PV; routine histopathology shows a predominately neutrophilic infiltrate, and DIF resembles that of BP [5].

The patient continued to flare uncontrollably with dupilumab, which was discontinued in favor of an increase to prednisone 100 mg daily, two infusions of rituximab 1000 mg spaced two weeks apart, and initiation of dapsone 100 mg daily. He has experienced promising improvement and is now on prednisone 60 mg daily one month after the second dose of rituximab.

Discussion

Rare forms of pemphigoid, including anti-p200 pemphigoid, may present a diagnostic challenge to clinicians, mimicking a variety of more common AIBDs both clinically and histopathologically [3]. A 2019 systematic review of 113 anti-p200 pemphigoid patients found that the disease most often clinically resembles BP (66% cases) and rarely mimics other AIBDs such as linear IgA bullous dermatosis, EBA, DH, and MMP [3]. Prominent mucosal, palmoplantar, and cephalic involvement should heighten suspicion for anti-p200 pemphigoid, and scarring and milia are observed in a minority of patients (~15% cases) [3]. An association with psoriasis has also been reported [3].

Biopsy of anti-p200 pemphigoid typically reveals a subepidermal blister with a neutrophilic or mixed inflammatory infiltrate, although papillary microabscesses and a neutrophilic or eosinophilic spongiotic component may be present [6-7]. A linear band of IgG and/or C3 with an n-serrated pattern on DIF is characteristic [2-3,7]. The u-serrated pattern is unique to anti-type VII collagen diseases (i.e., EBA and bullous SLE), highlighting the localization of type VII collagen to the sublamina densa [8]. The n-serration pattern seen in other forms of pemphigoid, including anti-p200 pemphigoid, corresponds to targets within...
or superior to the lamina densa [8-9].

IIF on salt-split skin helps distinguish anti-p200 pemphigoid from BP and most forms of MMP. Dermal (floor) localization is observed in the former and epidermal (roof) localization in the latter two entities [5,10]. As anti-laminin 332 MMP, anti-p200 pemphigoid, and presumably anti-p105 pemphigoid (given its antigen location in the lower lamina lucida) all demonstrate an n-serration pattern on DIF and dermal binding on IIF, further testing is required to distinguish these entities [8]. However, due to the complexity of workup and lack of access to confirmatory tests, it is likely that they have been widely underdiagnosed [5,7].

Conclusions

This case demonstrates that despite supportive histopathology and DIF, suspicion for another AIBD is necessary in cases of treatment-refractory and clinically aberrant BP. IIF on salt-split skin can assist in differentiating BP from rarer forms of pemphigoid. Furthermore, examination of the serration pattern on DIF can aid in distinguishing anti-type VII collagen disorders from other subepidermal bullous diseases. Clinicians should be aware that limited workup may lead to a missed diagnosis and less efficient management of the actual disease.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Miyamoto D, Santi CG, Aoki V, Maruta CW: Bullous pemphigoid. An Bras Dermatol. 2019, 94:133–46. 10.1590/abd1806-4841.20190007
2. Rose C, Weyers W, Denisjak N, Hillen U, Zillikens D, Shimanovich I: Histopathology of anti-p200 pemphigoid. Am J Dermatopathol. 2007, 29:119–24. 10.1097/DAD.0b013e31803526e6
3. Kridin K, Ahmed AR: Anti-p200 pemphigoid: a systematic review. Front Immunol. 2019, 10:2466. 10.3389/fimmu.2019.02466
4. Lau I, Goletz S, Holtsche MM, Zillikens D, Fechner K, Schmidt E: Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by indirect immunofluorescence microscopy on human salt-split skin. J Am Acad Dermatol. 2019, 81:1195–7. 10.1016/j.jaad.2019.03.077
5. Chan LS, Cooper KD: A novel immune-mediated subepidermal bullous dermatosis characterized by IgG autoantibodies to a lower lamina lucida component. Arch Dermatol. 1994, 130:343–7. 10.1001/archderm.1994.01690030075012
6. Meijer JM, Diercks GF, Schmidt E, Pas HH, Jonkman MF: Laboratory diagnosis and clinical profile of anti-p200 pemphigoid. JAMA Dermatol. 2016, 152:897–904. 10.1001/jamadermatol.2016.1099
7. García-Díez I, Martínez-Escala ME, Ishii N, et al.: Usefulness of a simple immunohistochemical staining technique to differentiate anti-p200 pemphigoid from other autoimmune blistering diseases: a report of 2 cases. Actas Dermosifiliogr. 2017, 108:e1–e5. 10.1016/j.ad.2015.10.019
8. Vodegel RM, Jonkman MF, Pas HH, de Jong MC: U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol. 2004, 151:112–8. 10.1111/j.1365-2133.2004.06006.x
9. Witte M, Zillikens D, Schmidt E: Diagnosis of autoimmune blistering diseases. Front Med (Lausanne). 2018, 5:296. 10.3389/fmed.2018.00296
10. Bolognia JL, Schaffer JV, Cerroni L: Dermatology. Elsevier Inc., Amsterdam, Netherlands; 2018.